Project Details
Description
Huntington’s disease (HD) is a devastating neurodegenerative disease (ND) that affects approximately 30,000
patients in United States and for which no therapies are available. HD is characterized by massive protein
aggregation, preferentially affecting medium spiny neurons (MSNs) in the striatum. Despite numerous studies
addressing the importance of MSN degeneration in HD pathology, very little is known about the molecular
mechanisms by which mutant huntingtin (mHTT) protein induces MSN death in HD.
Recent evidence demonstrated that the essential heat shock transcription factor 1 (HSF1), responsible for the
expression of stress protective proteins, is inappropriately degraded in MSNs in HD. We hypothesize that
HSF1 degradation is a key pathway involved in MSN dysfunction and loss in HD and preventing its
degradation may constitute a potential therapeutic approach. The goal of this proposal is to characterize the
mechanism that leads to HSF1 degradation in MSNs, and determine if reversal of this process, even after
onset of HD symptoms leads to improved outcomes. In Aim 1 we will test the hypothesis that inappropriate
accumulation of the protein p53 in MSNs controls the expression of components of the HSF1 degradation
pathway (protein kinase CK2α’ and E3 ligase Fbxw7), ultimately leading to loss of HSF1 and HD
symptomology. This pathway would be preferentially activated in MSNs due to the enhanced CAG somatic
instability observed in the striatum. To test this hypothesis, we will use molecular, pharmacological and genetic
manipulations in primary neurons and transgenic HD mice. The expected results will reveal the mechanism/s
by which MSNs become dysfunctional in HD and establish the basis for future understanding of the preferred
susceptibility of MSNs to mHTT.
Several studies have attempted to pharmacologically activate HSF1 as a therapeutic approach in HD, but they
failed in achieving long-term benefits. We propose that preventing HSF1 degradation may be a more effective
and long-lasting therapeutic strategy. In Aim 2 we will use pharmacological and genetic manipulations of
CK2α’ in HD mice to prevent HSF1 degradation at different time points during disease progression. These
studies will reveal the timeframe in which preventing HSF1 degradation is necessary to improve HD symptoms
and consolidate CK2α’ as a potential therapeutic target for HD. Changes in HSF1, p53 and CK2 are also
observed in other neurodegenerative diseases and therefore, our studies in HD may identify common HSF1
degradative mechanisms and therapeutic targets applicable to other NDs.
Status | Finished |
---|---|
Effective start/end date | 12/15/19 → 11/30/23 |
Funding
- National Institute of Neurological Disorders and Stroke: $304,007.00
- National Institute of Neurological Disorders and Stroke: $305,156.00
- National Institute of Neurological Disorders and Stroke: $336,875.00
- National Institute of Neurological Disorders and Stroke: $266,006.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.